Portuguese PT English EN Spanish ES

Case Study Details

  • Home
  • Pricing for CMED / ANVISA

Pricing for CMED / ANVISA

  • Problem Statement:
    The client has Oncology Portfolio and has two new technologies to be registered with CMED – Medicines Market Regulation Chamber. The usual approaches used by law firms and other consultancies were not considered appropriate.

Pricing for CMED / ANVISA

Proposed Solution:
MAPESolutions defined two approaches. In the first, more than 12 scenarios for CMED - Medicines Market Regulation Chamber - categories 1 and 2 were developed. The clinical approach was explored (our clinical analysis can establish several scenarios, generating various prices), as is done by CMED, an international price reference, and combining the two with the aim of maximizing the pricing approach. The different approaches were discussed with the Global Scenario and validated with internal country pricing data. With this we have improved knowledge of the CMED approach and internal information to build a robust DIP (CMED document for pricing).

Outcome:
MAPESolutions approach allows exploring several scenarios and a part of them was used to define the base scenario for submission, already prepared a data backset to discuss with CMED.